Cocrystal Pharma (COCP) Other Accumulated Expenses (2017 - 2026)

Cocrystal Pharma has reported Other Accumulated Expenses for 10 years, with the latest figure at $414000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 42.02% year-over-year to $414000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $414000.0 (down 42.02% YoY) and the FY2025 annual result came in at $901000.0, up 92.52% from the prior year.
• Other Accumulated Expenses slipped to $414000.0 in Q1 2026 per COCP's latest filing, from $901000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.7 million in Q4 2023 and troughed at $152000.0 in Q1 2023.
• A 5-year average of $557294.1 and a median of $468000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses tumbled 80.19% in 2022, then jumped 628.88% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $232000.0 in 2022, then surged by 628.88% to $1.7 million in 2023, then plunged by 72.32% to $468000.0 in 2024, then jumped by 92.52% to $901000.0 in 2025, then tumbled by 54.05% to $414000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $414000.0, $901000.0, and $322000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.